文献速递颈动脉与弓上血管

经颈动脉血运重建与经股动脉颈动脉支架置入术在血管外科学会血管质量倡议中的比较

Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2018-06-22

基于血管质量倡议(VQI)数据,比较经颈动脉血运重建(TCAR)与经股动脉颈动脉支架置入术(TFCAS)的院内结局。TCAR组638例,TFCAS组10136例。TFCAS组院内短暂性脑缺血发作/卒中及TIA/卒中/死亡发生率显著高于TCAR组(3.3% vs 1.9%,P=0.04;3.8% vs 2.2%,P=0.04)。多变量调整后TFCAS与TCAR相比卒中或死亡率有升高趋势但未达统计学显著(2.5% vs 1.7%;P=0.25;OR 1.75,95%CI 0.85-3.62)。

要点

  • TFCAS组院内TIA/卒中发生率3.3%,TCAR组1.9%(P=0.04)。
  • TFCAS组院内TIA/卒中/死亡发生率3.8%,TCAR组2.2%(P=0.04)。
  • 多变量调整后TFCAS与TCAR相比卒中或死亡率无统计学显著差异(2.5% vs 1.7%;P=0.25;OR 1.75,95%CI 0.85-3.62)。

核心结论

  • 与TFCAS患者相比,TCAR患者合并更多内科疾病,但卒中/死亡率相似,院内TIA/卒中/死亡风险降低一半。
  • 这些结果在严格调整和匹配潜在混杂因素后依然存在。
  • 这是首项在真实世界实践中证明TCAR优于TFCAS的研究,但为初步结果,需临床试验确认。

研究设计与样本

  • 血管外科学会VQI TCAR监测项目(TSP)旨在评估真实世界中TCAR的安全性和有效性。
  • 分析TSP自2016年3月至2017年12月最初入组的646例患者数据,并与2005年至2017年接受TFCAS的患者比较。
  • 排除串联、创伤性或夹层病变患者。
  • 采用多变量逻辑回归和1:1粗化精确匹配分析神经不良事件(卒中及短暂性脑缺血发作[TIA])和院内死亡率。

主要发现

  • 与TFCAS组(n=10136)相比,TCAR组(n=638)年龄显著更大、心脏合并症更多、更可能无症状、复发性狭窄更少。
  • TFCAS组院内TIA/卒中发生率3.3%,TCAR组1.9%(P=0.04);TFCAS组TIA/卒中/死亡发生率3.8%,TCAR组2.2%(P=0.04)。
  • 症状性患者TIA/卒中/死亡发生率高于无症状患者:TCAR组3.7% vs 1.4%(P=0.06);TFCAS组5.3% vs 2.7%(P<0.001)。
  • 多变量调整后TFCAS与TCAR相比卒中或死亡率有升高趋势但未达统计学显著(2.5% vs 1.7%;P=0.25;OR 1.75,95%CI 0.85-3.62)。
  • TFCAS与TCAR相比,院内不良神经事件及TIA/卒中/死亡的比值比为2.10(95%CI 1.08-4.08;P=0.03),不依赖于症状状态。

关键数值与推荐

  • TFCAS组院内TIA/卒中发生率3.3%,TCAR组1.9%(P=0.04)。
  • TFCAS组院内TIA/卒中/死亡发生率3.8%,TCAR组2.2%(P=0.04)。
  • 多变量调整后TFCAS与TCAR相比卒中或死亡率无统计学显著差异(2.5% vs 1.7%;P=0.25;OR 1.75,95%CI 0.85-3.62)。
  • TFCAS与TCAR相比院内不良神经事件及TIA/卒中/死亡的OR为2.10(95%CI 1.08-4.08;P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这是对VQI TSP的初步评估。
  • 这些结果需要临床试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent evidence from the Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER) multicenter trial in high-risk patients undergoing transcarotid artery stenting with dynamic flow reversal reported the lowest stroke rate compared with any prospective trial of carotid artery stenting. However, clinical trials have selection criteria that exclude many patients from enrollment and are highly selective of operators performing the procedures, which limit generalizability. The aim of this study was to compare in-hospital outcomes after transcarotid artery revascularization (TCAR) and transfemoral carotid artery stenting (TFCAS) as reported in the Vascular Quality Initiative (VQI). METHODS: The Society for Vascular Surgery VQI TCAR Surveillance Project (TSP) was designed to evaluate the safety and effectiveness of TCAR in real-world practice. Data from the initial 646 patients enrolled in the TSP from March 2016 to December 2017 were analyzed and compared with those of patients who underwent TFCAS between 2005 and 2017. Patients with tandem, traumatic, or dissection lesions were excluded. Multivariable logistic regression and 1:1 coarsened exact matching were used to analyze neurologic adverse events (stroke and transient ischemic attacks [TIAs]) and in-hospital mortality. Patients in the two procedures were matched on age, ethnicity, coronary artery disease, congestive heart failure, prior coronary artery bypass graft or percutaneous coronary intervention, chronic kidney disease, degree of ipsilateral stenosis, American Society of Anesthesiologists class, symptomatic status, restenosis, anatomic and medical risk, and urgency of the procedure. RESULTS: Compared with patients undergoing TFCAS (n = 10,136), those undergoing TCAR (n = 638) were significantly older, had more cardiac comorbidities, were more likely to be asymptomatic, and were less likely to have a recurrent stenosis. The rates of in-hospital TIA/stroke as well as of TIA/stroke/death were significantly higher in TFCAS compared with TCAR (3.3% vs 1.9% [P = .04] and 3.8% vs 2.2% [P = .04], respectively). In both procedures, symptomatic patients had higher rates of TIA/stroke/death compared with asymptomatic patients (TCAR, 3.7% vs 1.4% [P = .06]; TFCAS, 5.3% vs 2.7% [P < .001]). After multivariable adjustment, there was a trend of increased stroke or death rates in TFCAS compared with TCAR, but it was not statistically significant (2.5% vs 1.7%; P = .25; odds ratio, 1.75, 95% confidence interval, 0.85-3.62). However, TFCAS was associated with twice the odds of in-hospital adverse neurologic events and TIA/stroke/death compared with TCAR (odds ratio, 2.10; 95% confidence interval, 1.08-4.08; P = .03), independent of symptom status. Coarsened exact matching showed similar results. CONCLUSIONS: Compared with patients undergoing TFCAS, patients undergoing TCAR had significantly more medical comorbidities but similar stroke/death rates and half the risk of in-hospital TIA/stroke/death. These results persisted despite rigorous adjustment and matching of potential confounders. This initial evaluation of the VQI TSP demonstrates the ability to rapidly monitor new devices and procedures using the VQI. Although it is preliminary, this is the first study to demonstrate the benefit of TCAR compared with TFCAS in real-world practice. These results need to be confirmed by a clinical trial.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas MB, Dakour-Aridi H, Wang GJ, et al. Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg. 2018. PMID: 29941316. doi:10.1016/j.jvs.2018.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。